Trustmark National Bank Trust Department Has Increased By $1.04 Million Its Glaxosmithkline Plc (GSK) Holding; Xencor (XNCR) Sellers Increased By 1.54% Their Shorts

February 15, 2018 - By Kurt Siggers

Xencor Incorporated (NASDAQ:XNCR) had an increase of 1.54% in short interest. XNCR’s SI was 3.29 million shares in February as released by FINRA. Its up 1.54% from 3.24 million shares previously. With 254,600 avg volume, 13 days are for Xencor Incorporated (NASDAQ:XNCR)’s short sellers to cover XNCR’s short positions. The SI to Xencor Incorporated’s float is 8.42%. The stock increased 0.95% or $0.23 during the last trading session, reaching $24.5. About 107,231 shares traded. Xencor, Inc. (NASDAQ:XNCR) has risen 73.89% since February 15, 2017 and is uptrending. It has outperformed by 57.19% the S&P500.

Trustmark National Bank Trust Department increased Glaxosmithkline Plc (GSK) stake by 181.56% reported in 2017Q3 SEC filing. Trustmark National Bank Trust Department acquired 26,019 shares as Glaxosmithkline Plc (GSK)’s stock rose 5.47%. The Trustmark National Bank Trust Department holds 40,350 shares with $1.64M value, up from 14,331 last quarter. Glaxosmithkline Plc now has $83.20B valuation. The stock increased 1.11% or $0.41 during the last trading session, reaching $37.23. About 2.27M shares traded. GlaxoSmithKline plc (NYSE:GSK) has risen 4.26% since February 15, 2017 and is uptrending. It has underperformed by 12.44% the S&P500.

Among 7 analysts covering Xencor (NASDAQ:XNCR), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Xencor had 12 analyst reports since August 5, 2015 according to SRatingsIntel. The company was maintained on Thursday, September 17 by Leerink Swann. Canaccord Genuity maintained it with “Buy” rating and $36.0 target in Monday, November 13 report. Piper Jaffray initiated the stock with “Overweight” rating in Tuesday, October 4 report. The firm has “Hold” rating given on Friday, September 4 by Zacks. The firm has “Buy” rating given on Sunday, November 12 by Piper Jaffray. As per Saturday, August 8, the company rating was downgraded by Zacks. As per Tuesday, November 28, the company rating was initiated by Cantor Fitzgerald. The stock of Xencor, Inc. (NASDAQ:XNCR) has “Buy” rating given on Tuesday, December 22 by Canaccord Genuity. Canaccord Genuity maintained it with “Buy” rating and $3600 target in Monday, August 7 report. The firm has “Outperform” rating by Leerink Swann given on Tuesday, March 8.

Since August 16, 2017, it had 3 insider purchases, and 0 insider sales for $3.97 million activity. 9,215 shares were bought by STAFFORD JOHN S III, worth $191,280.

Investors sentiment decreased to 0.9 in Q3 2017. Its down 0.01, from 0.91 in 2017Q2. It fall, as 14 investors sold Xencor, Inc. shares while 34 reduced holdings. 14 funds opened positions while 29 raised stakes. 36.12 million shares or 0.72% more from 35.87 million shares in 2017Q2 were reported. Piermont Mgmt stated it has 0.08% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). Deutsche Bank Ag holds 88,687 shares or 0% of its portfolio. Northern Trust has invested 0% in Xencor, Inc. (NASDAQ:XNCR). Sg Americas Secs Limited Liability has invested 0% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). Victory Cap Mngmt invested 0% in Xencor, Inc. (NASDAQ:XNCR). Legal General Grp Public Limited Co reported 0% stake. Dupont Capital Corp stated it has 0.02% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). Cannell Peter B And Commerce Inc holds 0.16% or 200,100 shares in its portfolio. Atlantic Tru Grp Limited Co holds 0% or 40,823 shares. California State Teachers Retirement System owns 60,636 shares. Principal Fincl Group Inc holds 0% in Xencor, Inc. (NASDAQ:XNCR) or 8,790 shares. Tower Rech Limited Liability Company (Trc) reported 0.01% stake. Ecor1 Ltd Limited Liability Company reported 90,114 shares. New York-based Group Inc Inc has invested 0% in Xencor, Inc. (NASDAQ:XNCR). Ameritas Ptnrs Inc reported 3,040 shares.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company has market cap of $1.15 billion. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. It currently has negative earnings. The companyÂ’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies.

Trustmark National Bank Trust Department decreased Prospect Capital Corporation (NASDAQ:PSEC) stake by 141,451 shares to 215,890 valued at $1.45M in 2017Q3. It also reduced Ishares (PFF) stake by 56,267 shares and now owns 152,944 shares. Vanguard (VCSH) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: